Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in perinatal asphyxia

Brain and Development

Volumn 31, Issue 8, 2009, Pages 588-593

  Sunagawa, Shinpei ^a   Ichiyama, Takashi ^a   Honda, Rie ^a   Fukunaga, Shinnosuke ^a   Maeba, Shinji ^a   Furukawa, Susumu ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Asphyxia; Matrix metalloproteinase 9; Neonates; Tissue inhibitor of metalloproteinase 1

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BLOOD BRAIN BARRIER; CEREBRAL PALSY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; MALE; NEWBORN; PATHOGENESIS; PERINATAL ASPHYXIA; PROGNOSIS; QUADRIPLEGIA;

ASPHYXIA NEONATORUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MATRIX METALLOPROTEINASE 9; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 67651222272     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.braindev.2008.09.001     Document Type: Article

References (32)

1. Dilenge M.E., Majnemer A., and Shevell M.I. Long-term developmental outcome of asphyxiated term neonates. J Child Neurol 16 (2001) 781-792
2. Boichot C., Walker P.M., Durand C., Grimaldi M., Chapuis S., Gouyon J.B., et al. Term neonate prognoses after perinatal asphyxia: contributions of MR imaging, MR spectroscopy, relaxation times, and apparent diffusion coefficients. Radiology 239 (2006) 839-848
3. Volpe J.J. Hypoxic-ischemic encephalopathy: clinical aspects. In: Volpe J.J. (Ed). Neurology of the Newborn. 4th ed. (2001), WB Saunders, Philadelphia 331-394
4. Tekgul H., Yalaz M., Kutukculer N., Ozbek S., Kose T., Akisu M., et al. Value of biochemical markers for outcome in term infants with asphyxia. Pediatr Neurol 31 (2004) 326-332
5. Patel J., and Edwards A.D. Prediction of outcome after perinatal asphyxia. Curr Opin Pediatr 9 (1997) 128-132
6. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C., et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72 (1997) 155-161
7. Chakraborti S., Mandal M., Das S., Mandal A., and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253 (2003) 269-285
8. Lukes A., Mun-Bryce S., Lukes M., and Rosenberg G.A. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 19 (1999) 267-284
9. Murphy G., and Knäuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol 15 (1997) 511-518
10. Lacraz S., Nicod L.P., Chicheportiche R., Welgus H.G., and Dayer J.M. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96 (1995) 2304-2310
11. Akisü M., and Kültürsay N. Value of the urinary uric acid to creatinine ratio in term infants with perinatal asphyxia. Acta Pediatr Jpn 40 (1998) 78-81
12. Yoon B.H., Park C.W., and Chaiworapongsa T. Intrauterine infection and the development of cerebral palsy. BJOG 110 (2003) 124-127
13. Fotopoulos S., Mouchtouri A., Xanthou G., Lipsou N., Petrakou E., and Xanthou M. Inflammatory chemokine expression in the peripheral blood of neonates with perinatal asphyxia and perinatal or nosocomial infections. Acta Pediatr 94 (2005) 800-806
14. Aly H., Khashaba M.T., El-Ayouty M., El-Sayed O., and Hasanein B.M. IL-1β, IL-6 and TNF-α and outcomes of neonatal hypoxic-ischemic encephalopathy. Brain Dev 28 (2006) 178-182
15. Hussein M.H., Daoud G.A., Kakita H., Hattori A., Murai H., Yasuda M., et al. The sex differences of cerebrospinal fluid levels of interleukin 8 and antioxidants in asphyxiated newborns. Shock 28 (2007) 154-159
16. Kaufman S.A., Miller S.P., Ferriero D.M., Glidden D.H., Barkovich A.J., and Partridge J.C. Encephalopathy as a predictor of magnetic resonance imaging abnormalities in asphyxiated newborns. Pediatr Neurol 28 (2003) 342-346
17. Hunt R.W., Nei J.J., Coleman L.T., Kean M.J., and Inder T.E. Apparent diffusion coefficient in the posterior limb of the internal capsule predicts outcome after perinatal asphyxia. Pediatrics 114 (2004) 999-1003
18. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., and Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29 (1998) 1020-1030
19. Gasche Y., Fujimura M., Morita-Fujimura Y., Copin J.C., Kawase M., Massengale J., et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: a possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 19 (1999) 1020-1028
20. Svedin P., Hagberg H., Sävman K., Zhu C., and Mallard C. Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci 27 (2007) 1511-1518
21. Krizanac-Bengez L., Hossain M., Fazio V., Mayberg M., and Janigro D. Loss of flow induces leukocyte-mediated MMP/TIMP imbalance in dynamic in vitro blood-brain barrier model: role of pro-inflammatory cytokines. Am J Physiol Cell Physiol 291 (2006) C740-C749
22. Sellner J., and Leib S.L. In bacterial meningitis cortical brain damage is associated with changes in parenchymal MMP-9/TIMP-1 ratio and increased collagen type IV degradation. Neurobiol Dis 21 (2006) 647-656
23. Yamamoto S., and Nguyen J.H. TIMP-1/MMP-9 imbalance in brain edema in rats with fulminant hepatic failure. J Surg Res 134 (2006) 307-314
24. Förster C., Kahles T., Kietz S., and Drenckhahn D. Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol 580 (2007) 937-949
25. Ichiyama T., Kajimoto M., Suenaga N., Maeba S., Matsubara T., and Furukawa S. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis. J Neuroimmunol 172 (2006) 182-186
26. Ichiyama T., Siba P., Suarkia D., Takasu T., Miki K., Kira R., et al. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis. J Neurol Sci 252 (2007) 45-48
27. Ichiyama T., Morishima T., Kajimoto M., Matsushige T., Matsubara T., and Furukawa S. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in influenza-associated encephalopathy. Pediatr Infect Dis J 26 (2007) 542-544
28. Suenaga N., Ichiyama T., Kubota M., Isumi H., Tohyama J., and Furukawa S. Roles of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in acute encephalopathy following prolonged febrile seizures. J Neurol Sci 266 (2008) 126-130
29. Shiraishi M., Ichiyama T., Matsushige T., Iwaki T., Iyoda K., Fukuda K., et al. Soluble tumor necrosis factor receptor 1 and tissue inhibitors of metalloproteinases-1 in hemolytic uremic syndrome with encephalopathy. J Neuroimmunol 196 (2008) 147-152
30. 2 as a trigger and NF-κB as a signal transducer. Thromb Haemost 90 (2003) 528-537
31. Rosell A., Ortega-Aznar A., Alvarez-Sabín J., Fernández-Cadenas I., Ribó M., Molina C.A., et al. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37 (2006) 1399-1406
32. Hasegawa K., Ichiyama T., Isumi H., Nakata M., Sase M., and Furukawa S. NF-κB activation in peripheral blood mononuclear cells in neonatal asphyxia. Clin Exp Immunol 132 (2003) 261-264